Everence Capital Management’s Medifast MED Stock Holding History

Everence Capital Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,780	Closed	-$205K	–	778
2022 Q4	$205K	Buy	+1,780	New	+$207K	0.02%	687
2022 Q3	–	Sell	-1,780	Closed	-$321K	–	740
2022 Q2	$321K	Hold	1,780	–	–	0.03%	494
2022 Q1	$304K	Sell	1,780 -630	-26%	-$119K	0.02%	555
2021 Q4	$505K	Buy	2,410 +610	+34%	+$126K	0.04%	409
2021 Q3	$347K	Hold	1,800	–	–	0.03%	521
2021 Q2	$509K	Hold	1,800	–	–	0.04%	391
2021 Q1	$381K	Sell	1,800 -510	-22%	-$122K	0.03%	462
2020 Q4	$454K	Hold	2,310	–	–	0.04%	368
2020 Q3	$380K	Buy	+2,310	New	+$380K	0.04%	381
2019 Q3	–	Sell	-1,770	Closed	-$227K	–	656
2019 Q2	$227K	Hold	1,770	–	–	0.04%	515
2019 Q1	$226K	Hold	1,770	–	–	0.04%	500
2018 Q4	$221K	Hold	1,770	–	–	0.05%	360
2018 Q3	$392K	Sell	1,770 -540	-23%	-$109K	0.08%	267
2018 Q2	$370K	Hold	2,310	–	–	0.08%	271
2018 Q1	$216K	Buy	+2,310	New	+$173K	0.05%	380

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Everence Capital Management's MED Position: Q1 2023 in Review

Everence Capital Management sold out of Medifast (MED) in Q1 2023, closing a stake of 1,780 shares — an estimated $205K sold.

Everence Capital Management first reported a position in MED in Q1 2018 and held it in 15 quarters. The position peaked at $509K in Q2 2021. 267 funds tracked by Wall St. Rank hold MED as of Q1 2023.

Everence Capital Management reported no remaining Medifast position as of Q1 2023 after selling out during the quarter.
Everence Capital Management sold 1,780 Medifast shares in Q1 2023, an estimated $205K.
Everence Capital Management first reported a position in Medifast in Q1 2018 and held it in 15 quarters.
Everence Capital Management's Medifast position peaked at $509K in Q2 2021.
267 funds tracked by Wall St. Rank held Medifast as of Q1 2023.

Based on Everence Capital Management's 13F filing for Q1 2023, filed 4 Apr 2023.